NASDAQ
CDNA
Last Price
US $47.38
KEY FIGURES
MKT CAP
$2.5B
EPS
TTM
$2.16
EPS Growth (1Y)
-143.01%
PEG
TTM
-
P/E
TTM
21.97x
P/S
TTM
5.32x
YIELD
-
GROWTH (5Y CAGR)
Profit margin
Current Ratio
Capital Returns
32.81%
Return on equity
ROIC: -0.92%
Valuation History
22.0X
Price to Earnings
EV/EBITDA: 134.8X
Cash flow
Profit margin
Revenue
14.59%
EBITDA
11.91%
Cash flow
9.38%
Cash Flow (DCF)
Fair Value
Market $47.38
-72.46%
Default assumptions
EBITDA Multiple
Fair Value
Market $47.38
-98.31%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Cash flow to debt coverage
CareDx, Inc cash flow to debt ratio of 160.46% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Free cash flow growth
CareDx, Inc's free cash flow has increased 14.43% from $31.56M last year to $36.12M, signaling increasing performance
Debt-to-equity ratio
CareDx, Inc's debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
CareDx, Inc's debt has decreased relative to shareholder equity from 0.07 last year to 0.05 today, signaling strengthened financials
Net debt to EBITDA
CareDx, Inc has a net cash position, so leverage is healthy.
Interest coverage
CareDx, Inc earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
CareDx, Inc's profit margin has increased (53.93%) in the last year from 15.74% to 24.23%, signaling increasing performance
Current ratio
CareDx, Inc's short-term assets of $257.13M exceed its short-term liabilities of $89.85M
Return on assets
CareDx, Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
CareDx, Inc's return on equity of 32.81%, is higher than 15.00%, indicating good performance
Earnings quality
CareDx, Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
CareDx, Inc had positive net income in only 1 out of 5 years, indicating unstable earnings
Positive free cash flow
CareDx, Inc has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
CareDx, Inc has a free cash flow yield of 1.48%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
CareDx, Inc's yearly earnings has decreased 140.64% since last year from $52.55M to $-21.35M, signaling decreasing performance
Revenue growth
CareDx, Inc's yearly revenue has increased 13.79% since last year from $333.79M to $379.81M, signaling increasing performance
Return on invested capital
ROIC -0.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
CareDx, Inc's 3-year revenue CAGR of 5.68% is positive, indicating growing revenue over the past 3 years
Revenue consistency
CareDx, Inc had revenue growth in 4 out of 5 years, indicating consistent revenue performance
Return on equity consistency
CareDx, Inc had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
CareDx, Inc is overvalued relative to its fair value price of 13.05 based on Discounted Cash Flow model
Earnings yield (TTM)
CareDx, Inc has an earnings yield of 4.58%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
EBITDA Valuation
CareDx, Inc is overvalued relative to its fair value price of 0.80 based on EBITDA multiple model
EV/EBITDA (FY)
CareDx, Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
CareDx, Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
CareDx, Inc has a price-to-book ratio of 5.69x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Price-to-sales ratio (TTM)
CareDx, Inc has a price-to-sales ratio of 5.29x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue